BioCentury
ARTICLE | Clinical News

ISIS-TTRRx regulatory update

August 13, 2012 7:00 AM UTC

Isis disclosed in its 2Q12 earnings that FDA granted Orphan Drug designation for ISIS-TTRRx to treat transthyretin (TTR) amyloidosis. The TTR antisense inhibitor is in Phase I testing to treat TTR fa...